A single monoclonal antibody, Fab5, has demonstrated effective protection against three distinct gammaherpesviruses. This includes the virus responsible for infectious mononucleosis. The research team isolated and characterized this broadly protective antibody, Fab5, which targets gammaherpesvirus gB, a crucial viral protein.
Developing broadly protective antibodies against diverse gammaherpesviruses has historically presented significant challenges. However, Fab5 exhibits effective protection across multiple host species and various viral strains, suggesting a breakthrough.
Based on its unique targeting mechanism and proven efficacy in animal models, Fab5 appears likely to advance as a leading candidate for a new generation of broad-spectrum antiviral therapies or vaccines.
How Fab5 Was Discovered
- The monoclonal antibody Fab5, isolated from EBV chimeric nanoparticle-immunized mice, shows broad and high affinity to γHV gB, according to Nature.
Fab5's successful isolation from immunized mice demonstrates a viable pathway for discovering potent antiviral antibodies, providing a foundation for future therapeutic development.
A Novel Target for Broad Protection
Fab5 targets an unreported γHV gB epitope that maintains antigenicity across the herpesvirus family and in both pre- and post-fusion states of gB, as detailed by Nature. This antibody targets a conserved and vulnerable epitope of gammaherpesvirus gB, which remains exposed in both pre-fusion and post-fusion states, according to PubMed. This unprecedented targeting of a conserved, exposed epitope is the core reason for Fab5's broad efficacy, making it a powerful tool against diverse gammaherpesviruses.
Fab5 in the Landscape of Antiviral Antibodies
A broadly neutralizing antibody, 16F9, disrupts the interaction between pre-gB and the gHgL complex, according to PubMed. This antibody, 16F9, also confers cross-genus protection. While other antibodies like 16F9 demonstrate broad protection through different mechanisms, Fab5's distinct epitope targeting offers a novel and potentially complementary strategy. The discovery of Fab5's unique, universally conserved gB epitope, highlighted by Nature, suggests that previous research efforts may have been looking in the wrong places, underscoring the need for novel approaches to long-standing viral challenges.
